Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T17:49:37.408Z Has data issue: false hasContentIssue false
  • English
  • Français

Cerebrospinal Fluid: When Is It Worthwhile to Do a Lumbar Puncture?

Published online by Cambridge University Press:  07 November 2014

Elaine R. Peskind
Elaine R. Peskind*
Affiliation:
Dr. Peskind is Associate Director of the Alzheimer’s Disease Research Center and Professor in the Department of Psychiatry and Behavioral Sciences at the, University of Washington, School of Medicine in Seattle, Washington
Get access Rights & Permissions [Opens in a new window]

Extract

Clinicians should have an understanding of a lumbar puncture is indicated in the differential diagnosis of dementia and delirium. In most cases, this procedure is not commonly performed in outpatient practice for the differential diagnosis of dementia. However, in patients who have acute or subacute onset or a very rapid decline—such as in suspected Creutzfeldt-Jakob disease (CJD)—cerebrospinal fluid (CSF) 14-3-3, and tau proteins can be diagnostic for at least sporadic CJD. Practice parameters from the American Academy of Neurology (AAN) suggest performing a spinal tap on patients ≤55 years of age. However, that recommendation may not always be beneficial, particularly in a patient who has a prominent family history of either Alzheimer’s disease (AD) or frontotemporal dementia. Per the AAN practice parameter, lumbar puncture for CSF analysis is indicated in the diagnosis of central nervous system (CNS) infection, carcinomatous meningitis, or CNS vasculitis.

Beyond the clinically indicated lumbar puncture, there is utility of CSF biomarkers, including CSF Aβ42, total tau, and phospho-tau, which are the best studied. These biomarkers may be useful for cases involving atypical presentations of dementia, eg, when it is difficult to determine if the patient has AD versus frontotemporal dementia. They may be most useful for cases in which there is an atypical presentation of the fluorodeoxyglucose PET image or PET image features of both AD and frontotemporal dementia.

Type
Research Article
Information
CNS Spectrums , Volume 13 , Issue S16 , 2008 , pp. 25 - 27
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Knopman, , et al.Practice Parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–1153.CrossRefGoogle Scholar
2.Peskind, ER, Riekse, R, Quinn, JF, et al.Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord. 2005;19(4):220–225.CrossRefGoogle ScholarPubMed
3.Sunderland, T, Linker, G, Mirza, N, et al.Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289(16):2094–2103.CrossRefGoogle ScholarPubMed
4.Galasko, D, Chang, L, Motter, R, et al.High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937–945.CrossRefGoogle ScholarPubMed
5.Hansson, O, Zetterberg, H, Buchhave, P, Londos, E, Blennow, K, Minthon, L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234.Google Scholar
6.Li, G, Sokal, I, Quinn, JF, et al.CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631–639.CrossRefGoogle ScholarPubMed
7.Fagan, AM, Roe, CM, Xiong, C, Mintun, MA, Morris, JC, Holtzman, DM. Cerebrospinal fluid tau/beta amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 64(3):343–349.Google Scholar
8.Peskind, ER, Li, G, Shofer, J, Quinn, JF, Kaye, JA, Clark, CM, Farlow, MR, DeCarli, C, Raskind, MA, Schellenberg, GD, Lee, VM, Galasko, DR. Age and apollipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognitiion. Arch Neurol. 2006;63:939–939.Google Scholar